Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24998621 | 0.85 | NR1D1 (0.35) | BRD4HTR3A | |
| SCHEMBL24998323 | 0.81 | CCR4 (0.39) | RORCPSIP1BRD4NR3C2 | |
| SCHEMBL24997620 | 0.70 | SCN9A (0.32) | — | |
| SCHEMBL19788942 | 0.68 | CCR4 (0.37) | RORCBRD4 | |
| SCHEMBL16154652 | 0.68 | CCR4 (0.41) | RORCBRD4KDM4EMAPTKMT2A | |
| SCHEMBL19788938 | 0.67 | CCR4 (0.40) | RORCALDH1A1TP53 | |
| SCHEMBL24997654 | 0.67 | SCN9A (0.35) | — | |
| SCHEMBL24142870 | 0.66 | BRD4 (0.46) | BRD4KDM4EMEN1MAPTKMT2A | |
| SCHEMBL19788718 | 0.66 | KAT2B (0.38) | — | |
| SCHEMBL24998325 | 0.64 | CCR4 (0.37) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230038823-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230038823-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | HAVCR2, MAVS, CD4 | RORC 702/4885PSIP1 2145/4885BRD4 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.